- Oslo Cancer Cluster - https://oslocancercluster.no -

What’s Hot & What’s Not in Immuno-Oncology Licensing

Tuesday, October 6, 2015 // 2:00-3:15pm EDT // 11:00am-12:15pm PDT US

Join a live web panel, hosted by ShareVault, Defined Health, Pullan Consulting and the Biotechnology Industry Organization (BIO), discussing what’s exciting and not so exciting in immuno-oncology drug development, and why.

For the live event, biotech licensing and pharmaceutical business development consultant Linda Pullan will be joined by four panelists who are business development experts from global pharmaceutical companies, a leading academic cancer center, and a top business development consulting firm. The panelists will discuss whether it is too late to get into PD1 and other checkpoint inhibitors, how they judge immuno-oncology combinations, if CAR-T can go into solid tumors, the impact of business models on cell therapy, winning strategies for deals in immuno-oncology licensing, and more.

The panelists will also respond to questions from the audience.

If you are developing an immuno-oncology drug or working toward in- or out-licensing one, you will want to hear these perspectives.